Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients
Abstract: Prostate cancer is a
malignancy in urology with the highest incidence metastasize to the bone up to
70%. The incidence of skeletal related event (SRE) by 46.1% such as severe
pain, pathologic fractures, spinal compression syndrome and hypercalcemia, with
a consequence of higher inpatient care and worsen the patient’s prognosis.
Androgen deprivation therapy (ADT) as a metastatic prostate cancer
treatment itself causes an osteopenia or osteoporosis.
Bisphosphonate inhibits normal and pathologic osteoclast-mediated bone
resorption by several mechanisms. Denosumab is the latest treatment option in
bone metastases. Multi-study shows the efficacy of denosumab is better than
zoledronic acid for SRE prevention. Adverse events between denosumab and
bisphosphonate are comparable.
Key words: prostate cancer,
bone metastases, bone loss, treatment
Author: Ferry Safriadi
Journal Code: jpkedokterangg130287
